Statistics

Total Visits

Views
Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)38

Select a period of time:

Number of views in the range

Views
Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)3

Views

Views
May 20250
June 20251
July 20252
August 20250
September 20250
October 20250
November 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Austria2
Turkey1
 

Top cities views

Views
Bursa1
Vienna1